Safety and Targeting of Anti-hk2 Antibody in mCRPC

Conditions:   Castration-Resistant Prostatic Cancer;   Metastatic Disease Intervention:   Drug: 111In-DOTA-h11B6 Sponsors:   Tomopath Inc.;   Invicro;   Janssen Research & Development, LLC Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials